Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 11/20 | 0.73 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | MBOAT4 | Q96T53 | 4/20 | 0.60 |
| ▸ | USP7 | Q93009 | 2/20 | 0.60 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | STAT3 | P40763 | 1/20 | 0.60 |
| ▸ | CCR6 | P51684 | 1/20 | 0.54 |
| ▸ | RORC | P51449 | 1/20 | 0.53 |
| ▸ | F3 | P13726 | 1/20 | 0.34 |
| ▸ | PNLIP | P16233 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12136833 | 1.00 | NOS2 (0.73) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL84160 | 0.93 | NOS2 (0.63) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13393866 | 0.93 | CYP3A4 (0.73) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12447479 | 0.93 | CYP3A4 (0.73) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL82937 | 0.93 | CYP3A4 (0.73) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL10175977 | 0.92 | NOS2 (0.62) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL82953 | 0.92 | NOS2 (0.62) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL10175989 | 0.91 | NOS2 (0.60) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL83431 | 0.91 | MBOAT4 (0.62) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12447445 | 0.91 | MBOAT4 (0.62) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919838-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | Reata Pharmaceuticals Holdings, LLC (US) | 2024-03-05 | — | — | US | disclosed |
| US-11911395-B2 | Methods of treating obesity using antioxidant inflammation modulators | Reata Pharmaceuticals Holdings, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11873320-B2 | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof | Reata Pharmaceuticals Holdings, LLC (US) | 2024-01-16 | — | — | US | disclosed |
| US-20180161311-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | REATA PHARMACEUTICALS, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180094020-A1 | 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | Reata Pharmaceuticals Holdings, LLC | 2018-04-05 | — | — | US | disclosed |
| US-9889143-B2 | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof | REATA PHARMACEUTICALS, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20180009839-A1 | 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| US-9856286-B2 | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof | ABBVIE INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170333450-A1 | COMPOSITIONS AND METHODS FOR TREATING HIV-ASSOCIATED COGNITIVE DYSFUNCTION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2017-11-23 | — | — | US | disclosed |
| US-9757359-B2 | Synthetic triterpenoids and methods of use in the treatment of disease | REATA PHARMACEUTICALS, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-7915402-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring | REATA PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20110009363-A1 | SYNTHESIS AND BIOLOGICAL ACTIVITIES OF NEW TRICYCLIC-BIS-ENONES (TBES) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | disclosed |
| US-7714012-B2 | Synthesis and biological activities of new tricyclic-bis-enones (TBEs) | TRUSTEES OF DARTMOUTH UNIVERSITY (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100056777-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH SATURATION IN THE C-RING | REATA PHARMACEUTICALS, INC. | 2010-03-04 | — | — | US | disclosed |
| US-20100048892-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | REATA PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100048911-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: NOVEL DERIVATIVES OF OLEANOLIC ACID | REATA PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20090326063-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | REATA PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090060873-A1 | Novel synthetic triterpenoids and methods of use in the treatment and prevention of multiple scleroris | REATA PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090048205-A1 | COMBINATION THERAPY WITH SYNTHETIC TRITERPENOIDS AND GEMCITABINE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2009-02-19 | — | — | US | disclosed |
| US-20080261985-A1 | SYNTHESIS AND BIOLOGICAL ACTIVITIES OF NEW TRICYCLIC-BIS-ENONES (TBES) | TRUSTEES OF DARTMOUTH COLLEGE | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333450-A1 | COMPOSITIONS AND METHODS FOR TREATING HIV-ASSOCIATED COGNITIVE DYSFUNCTION | CD14, CCL2, CCR5 | NOS2 14/4885KEAP1 107/4885CYP3A4 1565/4885 |
| US-11911395-B2 | Methods of treating obesity using antioxidant inflammation modulators | TXNRD2, HMOX1, GPX4 | NOS2 83/4885KEAP1 60/4885CYP3A4 2104/4885 |
| US-20080261985-A1 | SYNTHESIS AND BIOLOGICAL ACTIVITIES OF NEW TRICYCLIC-BIS-ENONES (TBES) | HMOX1, MCL1, HMOX2 | NOS2 7/4885KEAP1 38/4885CYP3A4 68/4885 |
| US-20090326063-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | LIPG, CYP27A1, CYP11B1 | NOS2 378/4885KEAP1 444/4885CYP3A4 752/4885 |
| US-20180161311-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | LIPG, CYP27A1, CYP11B1 | NOS2 378/4885KEAP1 444/4885CYP3A4 752/4885 |
| US-20090048205-A1 | COMBINATION THERAPY WITH SYNTHETIC TRITERPENOIDS AND GEMCITABINE | RABGGTB, BAD, PGGT1B | NOS2 3154/4885KEAP1 1567/4885CYP3A4 1771/4885 |
| US-20110009363-A1 | SYNTHESIS AND BIOLOGICAL ACTIVITIES OF NEW TRICYCLIC-BIS-ENONES (TBES) | HMOX1, MCL1, HMOX2 | NOS2 7/4885KEAP1 38/4885CYP3A4 68/4885 |
| US-20090060873-A1 | Novel synthetic triterpenoids and methods of use in the treatment and prevention of multiple scleroris | GAP43, BDNF, PMP22 | NOS2 2334/4885KEAP1 261/4885CYP3A4 1761/4885 |
| US-11919838-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | IL17A, ALOX15, ALOX12 | NOS2 41/4885KEAP1 59/4885CYP3A4 679/4885 |
| US-20100056777-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH SATURATION IN THE C-RING | HMOX1, ALOX12, ALOX15 | NOS2 25/4885KEAP1 56/4885CYP3A4 483/4885 |
| US-20100048911-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: NOVEL DERIVATIVES OF OLEANOLIC ACID | ALOX12, NFE2L2, HMOX1 | NOS2 66/4885KEAP1 29/4885CYP3A4 1940/4885 |
| US-11873320-B2 | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof | CYP2A13, CYP4B1, CYP4A22 | NOS2 1348/4885KEAP1 1496/4885CYP3A4 86/4885 |
| US-20100048892-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | IL17A, ALOX15, ALOX12 | NOS2 41/4885KEAP1 59/4885CYP3A4 679/4885 |
| US-20180009839-A1 | 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | CYP2A13, CYP4B1, CYP4A22 | NOS2 1348/4885KEAP1 1496/4885CYP3A4 86/4885 |
| US-20180094020-A1 | 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | CYP2A13, CYP4B1, CYP4A22 | NOS2 1348/4885KEAP1 1496/4885CYP3A4 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.